Abstract-Calcium transients are known to control several transition points in the eukaryotic cell cycle. For example, we have previously shown that a coordinate elevation in the intracellular free calcium ion concentration is required for G 1 -to S-phase cell cycle progression in vascular smooth muscle cells (VSMC). However, the molecular basis for this Ca 2ϩ sensitivity was not known. Using buffers with differing [Ca 2ϩ ], we found that the kinase activity of mouse and human cyclin E/CDK2, but not other G 1 /S-associated cell cycle complexes, was responsive to physiological changes in [Ca 2ϩ ]. We next determined that this Ca 2ϩ -responsive kinase activity was dependent on a direct interaction between calmodulin (CaM), one of the major Ca 2ϩ -signal transducers of eukaryotic cells, and cyclin E. Pharmacological inhibition of CaM abrogated the Ca 2ϩ sensitivity of cyclin E/CDK2 and retarded mouse VSMC proliferation by causing G 1 arrest. We next defined the presence of a highly conserved 22 amino acid N-terminal CaM-binding motif in mammalian cyclin E genes (dissociation constant, 1.5Ϯ0.1 mol/L) and showed its essential role in mediating Ca 2ϩ -sensitive kinase activity of cyclin E/CDK2. 
V ascular smooth muscle cells (VSMC) are the endeffector organs in vasculoproliferative diseases such as atherosclerosis, restenosis, and hypertension. 1 Elucidating the molecular mechanisms underlying the growth of VSMC may help to design novel therapies aimed at preventing and treating these conditions.
Many studies have implicated Ca 2ϩ as a regulator of distinct "checkpoints" in the cell cycle of eukaryotes. 2 Mammalian cells appear most sensitive to the depletion of extracellular Ca 2ϩ at 2 points, in early G 1 and near the G 1 /S boundary. 3 In several cell types, DNA synthesis could be completely inhibited when extracellular Ca 2ϩ was chelated by EGTA or when the influx of extracellular Ca 2ϩ was blocked by cobalt. 4, 5 Specifically for VSMC, it has been reported that depletion of Ca 2ϩ stores in the G 1 phase of VSMC results in a profound G 1 arrest that is not overcome until internal Ca 2ϩ stores are replenished. 6, 7 We also found, in cultured VSMC, that intracellular Ca 2ϩ concentrations ([Ca 2ϩ ] i ) exhibit significant increases as a function of cell cycle, such that resting free [Ca 2ϩ ] i vary from Ϸ75 nmol/L at G 0 to Ϸ150 nmol/L at G 1 /S, whereas sarcoendoplasmic reticulum Ca 2ϩ ATPase (SERCA)-maintained releasable [Ca 2ϩ ] i vary from Ϸ100 nmol/L at G 0 to Ϸ500 nmol/L at G 1 /S. 8 -10 Importantly, preventing increases in resting and releasable [Ca 2ϩ ] i inhibited G 1 -to S-phase transitions. 8, 9 Similarly, SERCA inactivation by thapsigargin has been shown to lengthen the G 1 phase of HEK 293 cells. 11 Calmodulin (CaM), a small acidic protein of 16.7 kDa, is an important transducer of Ca 2ϩ signals in eukaryotic cells. It is recruited by a large number of proteins, collectively termed CaM-binding proteins (CaMBPs), through which Ca 2ϩ sensitivity is expressed in a variety of cell biological functions. 12 The role of CaM as a regulator of cell cycle progression has also been well established. 2 Early indications came from experiments in which the mitotic cycle was arrested by anti-CaM drugs added to proliferating cells or to cells reentering cell cycle under the influence of mitogens. 13 In addition, it was reported that monoclonal antibodies against CaM inhibited the synthesis of DNA in permeabilized cells. 14 Moreover, progression through G 1 and mitosis exit was observed to be sensitive to changes in the intracellular concentration of CaM. 15 Although others have suggested a role for CaM in the G 1 /S transition through the activation or expression of proteins involved in DNA replication, 16, 17 and the phosphorylation of the retinoblastoma protein (Rb), 18 the molecular and cell biological mechanisms through which Ca 2ϩ and or CaM exerted these effects remained obscure. Thus, the primary objectives of our study were to identify which cell cycle proteins expressed in VSMC were responsive to changes in [Ca 2ϩ ], and whether their Ca 2ϩ sensitivity was mediated by CaM, and how. Given that (1) cyclin E/CDK2 is an enzyme complex that is both rate limiting and essential for S phase entry 19, 20 and (2) cyclin E synthesis begins in G 1 and reaches a peak at the G 1 /S transition, 21, 22 we hypothesized that the cyclin E/CDK2 complex may mediate Ca 2ϩ sensitivity of the G 1 /S cell cycle transition of VSMC. The current study reports that this is the case and that specific CaM-cyclin E interactions underlie this.
Materials and Methods

Materials and Cell Culture
Purified active cyclin E/CDK2 and cyclin A/CDK2 were obtained from Upstate Biotechnology (Lake Placid, NY). CDK2 inhibitor II, KN-93, and cyclosporin A were obtained from Calbiochem (La Jolla, Calif). Calmidazolium, dithiothreitol (DTT), aprotinin, leupeptin, and other chemicals were purchased from Sigma (St Louis, Mo). Synthetic peptides were purchased from GenScript Corp (Piscataway, NJ).
The isolation and culture of primary mouse aortic VSMC and the characterization of MOVAS, a mouse VSMC line, have been described. 10 MOVAS were grown in DMEM (GIBCO/BRL, Gaithersburg, Md) supplemented with 10% FBS (Hyclone, Logan, Utah) and 1% penicillin-streptomycin (GIBCO/BRL). For serum starvation, cells were grown to 60% to 70% confluence, washed twice with PBS, and cultured in starvation medium (DMEM without FBS) for 48 hours to achieve G 0 arrest. Fresh DMEM with 10% FBS was used to initiate reentry into cell cycle, and cells were incubated for 16 hours to allow them to approach the G 1 /S transition or for 20 hours for S-phase synchronization. Primary mouse aortic SMC were grown in media supplemented with platelet-derived growth factor (PDGF) (50 ng/mL). G 0 synchronization in these cells was achieved with 72 hours of 0.25% FBS-supplemented DMEM. Progression to G 1 /S was brought about by stimulation with 10% FBS and 50 ng/mL PDGF for 24 hours.
Immunoprecipitation and Kinase Assays
SMC (5ϫ10 6 ) were harvested and resuspended with 2 mL of lysis buffer (50 mmol/L Tris [pH 7.4], 250 mmol/L NaCl, 5 mmol/L EDTA, 0.1% NP-40, 0.5 mmol/L DTT, 0.1 mmol/L Na 3 VO 4 , 5 g/mL leupeptin, 5 g/mL aprotinin, 2 mmol/L PMSF, and 10% glycerol). After homogenization, cell lysates were clarified by centrifugation at 12ϫ10 3 rpm, 4°C for 30 minutes, and the superna- 
Western Blot
Between 20 to 30 g of cell extracts were resolved by 12% SDS-PAGE and transferred to nitrocellulose membranes (Sigma, 0.2 mol/L pore size). Blots were blocked with 5% nonfat dry milk in TBS-T (10 mmol/L Tris [pH 8.0], 150 mmol/L NaCl, and 0.05% Tween-20) overnight at 4°C and then incubated for 3 hours at 25°C in TBS-T plus 3% nonfat dry milk containing primary Abs, including anti-cyclin E and -cyclin A (Upstate Biotechnology), -phospho-CDK2 at Thr 196 (Cell Signaling Technology, Danvers, MA), -CaM, -His probe, and -actin (Santa Cruz Biotechnology, Santa Cruz, Calif). Protein bands were detected with ECL Reagents (Amersham Pharmacia), with horseradish peroxidase-conjugated secondary goat anti-rabbit IgG (Santa Cruz Biotechnology). Quantification of band intensity was performed using Quantity One (Bio-Rad, Hercules, Calif).
CaM-Binding Analysis
Purified cyclin E/CDK2 and cyclin A/CDK2 (100 ng) (Upstate Biotechnology) complexes were diluted with Ca 2ϩ -binding buffer (50 mmol/L Tris [pH 7.5], 100 mmol/L NaCl, and 2 mmol/L CaCl 2 ) into a final 20 L and incubated with an equal volume of preequilibrated CaM-Sepharose 4B resin (Amersham Pharmacia) for 2 hours at 4°C. After centrifugation, the supernatant containing unbound proteins was removed and the resin was washed twice with the buffer used in the binding step. After removing buffer completely from the resin, SDS loading buffer with DTT was added to the dried resin to collect all proteins bound to CaM. The proteins were resolved by 12% SDS-PAGE and visualized by silver staining to determine the amount bound to resin-immobilized CaM.
Confocal Immunofluorescence
Methods and representative images used for analysis of the extent of CaM and cyclin E colocalization are shown in the online data supplement available at http://circres.ahajournals.org.
Flow Cytometric Analysis
Samples were prepared as previously described with minor modifications. 8 Cells were counted in a flow cytometer (FACScan; BD Biosciences, Franklin Lakes, NJ), and G 0 /G 1 , S, and G 2 /M cell percentages were calculated with Cell Quest software (BD Biosciences).
Fluorescence Titration
The methods used to determine the dissociation constant (K d ) for peptide-protein binding are detailed in the online data supplement.
Transfection
pIRESpuro3 plasmid vectors (Clontech, Palo Alto, Calif) harboring wild-type (wt) and N-terminal-deleted mutant (N␦) cyclin E were obtained by PCR amplification of a pECE human cyclin E plasmid (a generous gift of Dr Paul Hamel, University of Toronto) with oligonucleotides 5Ј-ccggaattcatgaaggaggacggcg-3Ј (forward wt cyclin E), 5Ј-ccggaattcatgccagatgaagaaatgg-3Ј (forward N␦ cyclin E), and 5Ј-ccggaattctcagtggtggtggtggtggtgcgccatttccggccc-3Ј (reverse for both). DNA sequences of each construct were confirmed by sequencing. Transfections were performed with the Lipofectamine 2000 reagent (Invitrogen, Carlsbad, Calif) according to the instructions of the manufacturer. Starting 48 hours posttransfection, MOVAS were cultured in the presence of 5 g/mL puromycin for 2 weeks.
Statistics
ANOVA, Student t test, and coefficients of variance tests were used as appropriate. Analyses were performed on SPSS version 13.0 (Chicago, Ill).
Results
Cyclin E/CDK2 Activity at the G 1 /S Transition of VSMC Is Ca 2؉ Sensitive
Kinase activities of cyclin E-IPd complexes from G 0 -and
, that histone-H1 kinase activity at G 1 /S was greater than at G 0 (2.4-fold; Figure  1A ). These data suggested a G 1 /S-associated increase in cyclin E/CDK2 activity, which has been reported previously. 23 Our first novel finding was that an increase in reaction buffer [Ca 2ϩ ] from 0 to 500 nmol/L consistently increased histone-H1 kinase-defined activity of cyclin E-IPd complexes from G 1 /S-(2.6-fold) but not G 0 -synchronized VSMC ( Figure 1A ). Identical results were obtained when the experiment was performed using CDK2-IPd complexes (G 1 /S: 2.7-fold; Figure 1B ). Experiments with CDK2 inhibitor II showed that the histone-H1 kinase-defined activity of cyclin E immunoprecipitates (IPs) was CDK2-dependent ( Figure  1C ). Of note, Rb kinase-defined activity of cyclin E IPs was also Ca 2ϩ responsive only at G 1 /S ( Figure 1D ). In addition, histone-H1 kinase activity of cyclin E-IPd complexes from primary mouse aortic VSMC exhibited the same Ca 2ϩ responsiveness as those from MOVAS (G 1 /S: 2.3-fold; Figure 1E ). As a next step, we determined that this enhancement was specific to an increased [Ca 2ϩ ] and not other divalent cations ( Figure 1F ).
Unlike cyclin E/CDK2, cyclin D/CDK4 and cyclin A/CDK2 exhibited different properties. Neither cyclin D-IPd complexes from early G 1 phase MOVAS nor cyclin A-IPd complexes from S-phase MOVAS ( Figure 1G) showed Ca 2ϩ responsive increases in histone-H1 kinase activity. In addition, purified cyclin A/CDK2 complexes did not exhibit the Ca 2ϩ sensitivity observed with purified cyclin E/CDK2 (Figure 1H) . Of interest, the ability of Ca 2ϩ to enhance histone-H1 kinase activity of purified cyclin E/CDK2 complexes (1.7-fold; Figure 1H ) was less than that observed in IPs of cell extracts (Ͼ2.5-fold; Figure 1A through 1F) , suggesting perhaps that factors other than those present in "purified" complexes participate in their Ca 2ϩ sensitivity.
Choi et al Ca 2؉ /CaM-Cyclin E-Dependent CDK2 Activity
Taken together, the above data showed that the activity of cyclin E/CDK2 on 2 important substrates (Rb and histone-H1) involved in the G 1 /S transition is Ca 2ϩ sensitive within the physiological range of [Ca 2ϩ ] i known to accompany this stage of the cell cycle in VSMC. 8 -10 These data implicated cyclin E/CDK2 as a potential mediator of the known Ca 2ϩ sensitivity of the G 1 /S transition of both primary mouse VSMC and the MOVAS cell line.
CaM and, to a Limited Extent, Calcineurin, but Not CaM-Activated Kinases, Transduce Ca 2؉ -Sensitive Cyclin E/CDK2 Activity in VSMC
We next explored what mediated the Ca 2ϩ sensitivity of cyclin E/CDK2. A potential role for CaM, among the major Ca 2ϩ signal-transducing proteins in eukaryotes, was examined first. When added to cell extracts, the potent CaM inhibitor calmidazolium inhibited cyclin E/CDK2 activity in a dose-dependent manner (Figure 2A) , suggesting a role for CaM in regulating cyclin E/CDK2 activity. As known downstream mediators of CaM-regulated cell cycle progression in various cell types, the potential roles of multifunctional CaM-activated kinases (CaMKs) and calcineurin were tested next. KN-93, an inhibitor of several CaMKs, 24 did not affect H1 kinase-defined cyclin E/CDK2 activity ( Figure 2B ). Only high concentrations of cyclosporin A (50 mol/L), an inhibitor of calcineurin, 25 exhibited at most 20% inhibition of cyclin E/CDK2 activity ( Figure 2C ).
To test directly whether CaM and calcineurin are necessary for Ca 2ϩ sensitivity of cyclin E/CDK2 activity, immunodepletion experiments were performed. To deplete CaM or calcineurin from cell extracts, immunoprecipitation (IP) was first performed with excess amounts of anti-CaM or anti-calcineurin Abs, followed by a second IP with anti-cyclin E Ab on CaM-or calcineurin-depleted cell extracts. CaM-depleted cell extracts did not exhibit any Ca 2ϩ -mediated stimulation of cyclin E/CDK2 activity, suggesting that CaM is essential for Ca 2ϩ sensitivity of cyclin E/CDK2 activity ( Figure 2D ). By contrast, calcineurin-depleted cell extracts still exhibited some Ca 2ϩ sensitivity ( Figure 2D ).
To determine whether CaM has a direct effect on cyclin E/CDK2 activity, purified CaM (Sigma; purity Ͼ95%) was titrated with a fixed amount of purified human cyclin E/CDK2. CaM increased cyclin E/CDK2 activity in a dosedependent manner only in the presence of Ca 2ϩ , an effect that was abolished by calmidazolium and W-13 (another CaM antagonist) ( Figure 2E ), suggesting that CaM has a direct stimulatory effect on cyclin E/CDK2 activity. W-12, an analog of W-13 with much lower CaM affinity, did not mimic the effect of W-13 ( Figure 2E) . Together, the above data suggested that the stimulatory effect of CaM on cyclin E/CDK2 activity was mediated primarily by a direct Ca 2ϩ -dependent mechanism involving CaM and cyclin E/CDK2, rather than through CaMKs or calcineurin. . Calmidazolium (CMZ), W-13, and W-12 (all 100 mol/L) were added to examine whether the enhancement of cyclin E/CDK2 activity was CaM dependent. All experiments were performed in triplicate on at least 2 separate occasions and have been normalized to the kinase activity at 0 drug or [Ca 2ϩ ]. *PϽ0.05, **PϽ0.01.
Interaction Between CaM and Cyclin E Is Essential for Ca 2؉ -Sensitive Kinase Activity of Cyclin E/CDK2
To explore further the mechanisms underlying CaMdependent Ca 2ϩ -sensitive cell cycle kinase activities in VSMC, we used a CaM-binding assay. Equal amounts of purified cyclin E/CDK2 and cyclin A/CDK2 were loaded on a CaM-Sepharose column, and silver-stained blots of bound and unbound fractions revealed binding between CaM and cyclin E but not between CaM and cyclin A ( Figure 3A) . With varying buffer [Ca 2ϩ ], these experiments revealed that the interaction between CaM and cyclin E occurs in a Ca 2ϩ -dependent manner (data not shown). These results were entirely consistent with the observed difference in Ca 2ϩ -sensitivities between cyclin E/CDK2 and cyclin A/CDK2 ( Figure 1H ). Moreover, these data further supported a direct interaction between CaM and cyclin E, not CDK2, as an essential requirement for Ca 2ϩ sensitivity of cyclin E/CDK2. Co-IP analysis between CaM and cyclin E revealed that the amount of CaM bound to cyclin E increased at G 1 /S ( Figure  3B ; 1.68-fold). The absence of any CaM in IPs that used a nonspecific Ab (anti-actin) supported further the specificity of the interaction between CaM and cyclin E. In addition, subcellular localizations of CaM and cyclin E were visualized in MOVAS by fluorescence confocal microscopy, and the proportion of cells showing strong colocalization signals were calculated in both G 0 -and G 1 /S-synchronized populations (nϭ1000 cells each). This analysis suggested a 62% increase in the number of nuclei with strong CaM and cyclin E colocalization at G 1 /S versus G 0 (378 versus 233; PϽ0.001; online data supplement), a result mirroring closely the observed increase (68%) in co-IP experiments ( Figure 3B ). This may be related to increased expression levels of CaM at G 1 /S ( Figure 3B ), a finding also reported by others, 13, 26 and/or the higher [Ca 2ϩ ] i of G 1 /S-, as compared with G 0 -synchronized cells. 8 -10 
Inhibition of CaM Retards the Proliferation of VSMC
Having demonstrated a putative molecular mechanism mediating Ca 2ϩ -sensitive G 1 /S transitions, we sought to directly test its physiological significance. Flow-assisted cell sorting analysis (FACS) of DNA content was performed to determine whether inhibition of CaM retards the cell cycle progression of VSMC. Whereas control experiments showed that 24.4% of primary mouse aortic SMC had entered S phase after 24 hours of serum stimulation, only 10.8% of cells treated with calmidazolium, and 12.6% of cells treated with W-13, had done so (PϽ0.001; Figure 4A ). A similar level of cell cycle inhibition was also observed in MOVAS (online data supplement). Western blot analysis in primary VSMC showed that the interaction between CaM and cyclin E was severely inhibited by calmidazolium ( Figure 4B , lanes 5 and 6), whereas the amounts of cyclin E and CaM itself were not ( Figure 4B,  lanes 2 and 3) . This result indicated that the observed decrease in cyclin E-CaM interaction is not simply attributable to the inhibition of cell cycle progression. Importantly, the level of Thr160-phosphorylated CDK2 (the active form of CDK2) was inhibited by calmidazolium treatment ( Figure  4B, lanes 2 and 3) .
Together, these data suggested (1) that CaM facilitates G 1 -to S-phase transitions in VSMC via binding to cyclin E and (2) that this interaction may play a role in activating CDK2.
Identification of the CaM-Binding Motif on Cyclin E
To provide a structural basis for our functional model, we next sought to identify the CaM-binding region on cyclin E. A CaM-target database (http://calcium.uhnres.utoronto.ca/ ctdb) 27 predicted a CaM-binding motif on human cyclin E with successively high probability scores ( Figure 5A ). This consisted of 22 amino acids near the N terminus of human cyclin E (amino acids 5 to 26), with 5 hydrophobic and 5 basic residues predicted to be critical for a hydrophobic interaction between CaM and cyclin E. We termed this motif the "calmodulin-binding sequence" (CBS) of cyclin E and noted that mouse and rat cyclin E genes also harbor this conserved sequence, whereas the Drosophila and Caenorhabditis elegans homologs do not ( Figure 5B ), a finding that may restrict the physiological relevance of this domain to mammals. Consistent with the results of our kinase activity assays, Figure 3 . Physical interaction between CaM and cyclin E. A, Silver staining for CaM-Sepharose 4B-bound cyclin E and cyclin A. Purified cyclin E/CDK2 and cyclin A/CDK2 (100 ng) were diluted in Ca 2ϩ -binding buffer and applied to a CaMSepharose 4B resin. Unbound proteins were collected (Un), and bound proteins (Bo) were eluted with SDS buffer after several washes. An identical amount of each protein loaded on the binding column was also electrophoresed (L). B, Western blot analysis of CaM in whole cell extracts and in cyclin E-IPd extracts from G 0 -and G 1 /S-synchronized primary mouse VSMC. Actin staining established protein loading. Representative blots from 3 separate experiments are shown with normalized band intensities. **PϽ0.01 vs G 0 .
no similar CBS was revealed in alignment and sequence analyses of all cyclins D and A.
To confirm the ability of the CBS of cyclin E to bind CaM, we performed tyrosine residue-based fluorescence titration experiments using purified peptides in vitro. Figure 5C 
N␦ Cyclin E Neither Binds CaM nor Exhibits Ca 2؉ Sensitivity
To investigate further the structural basis and functional importance of CaM-cyclin E interactions, expression vectors harboring either His-tagged full length (wt) or His-tagged N␦ mutant forms of human cyclin E (lacking amino acids 1 to 26)
were stably transfected into MOVAS ( Figure 6A ). Despite equal levels of His-tagged wt and N␦ cyclin E protein expression ( Figure 6B , left panel), co-IP analyses on G 1 /Ssynchronized cell populations indicated that only wt cyclin E could bind CaM ( Figure 6B , right panel). Moreover, histone-H1 kinase assays performed on G 1 /S-synchronized cells revealed that despite an equivalent level of activity at 0 nmol/L [Ca 2ϩ ] to wt cyclin E/CDK2, N␦ cyclin E/CDK2 complexes did not exhibit any appreciable Ca 2ϩ -sensitive enhancement of function. By contrast, IPd wt human cyclin E exhibited an identical level of Ca 2ϩ sensitivity as endogenous mouse cyclin E in vector only transfected cells (2.5-fold; Figure 6C ).
Discussion
This study was focused on identifying the molecular mechanism(s) underlying the poorly understood Ca 2ϩ sensitivity of the G 1 to S-phase cell cycle transition of VSMC. The results presented here implicate cyclin E/CDK2 in this process and show that a Ca 2ϩ -dependent binding of CaM to cyclin E at G 1 /S is critical for G 1 /S-and Ca 2ϩ -specific enhancement of cyclin E/CDK2 activity. We also defined a CaM-binding motif in the human cyclin E gene and demonstrated its essential role in mediating Ca 2ϩ -sensitive CDK2 activity. Although the expression of CDK2 in T lymphocytes was noted to be depressed by the CaM antagonist W-13, 29 our work is the first to show that CaM increases CDK2 activity via binding to cyclin E. This conclusion was supported by various analyses using several independent approaches including Western blot, co-IP, immunohistochemistry, peptide binding, and structure-function studies with mutants. To investigate further, fluorescence spectroscopy was used to calculate K d between the CBS peptide and CaM. The finding that N␦ cyclin E was unable to bind to CaM ( Figure 6B ) strongly suggested that this CaM-binding motif in human cyclin E1 (amino acids 5 to 26) is the only area involved in CaM-cyclin E interactions. As such, the determined K d obtained from CaM and the CBS peptide likely reflects the true dissociation constant between CaM and cyclin E. If the fluorescent residues examined were far from the binding site or were not involved in a binding-mediated conformational change, no changes in fluorescence would have been observed. 30 Rather, our experiments clearly support a structural relationship between the CBS and CaM with a K d consistent with other CaMBPs such as G protein-coupled receptor kinase 2, 31 caldesmon, calponin, 28 spectrin, 32 and CaMdependent adenylate cyclases. 33, 34 Although previous reports have suggested a role for CaM in cell cycle, 2 specific molecular pathways through which CaM might exert these effects were not known. Kahl and Means implicated CaM in the regulation of cyclin D1/CDK4 through their discovery that CaMKI, and not CaMKII, was the KN-93-sensitive CaMK responsible for KN-93-induced G 1 arrest in WI-38 fibroblasts. 35 They reported also that CaM activates cyclin D1 protein synthesis in fibroblasts via calcineurin. 36 Previously, Taules and colleagues had implicated CaM in the nuclear entry of cyclin D/CDK4 and identified a relevant interaction between CaM and the CDK4 inhibitor p21
Cip1 . 37, 38 In contrast to the work in other cell types, we did not find KN-93-sensitive CaMKs to be involved in mediating Ca 2ϩ /CaM sensitivity of cyclin E/CDK2 complexes and demonstrated a very modest effect of cyclosporin A and calcineurin immunodepletion. Rather, we have identified a physiologically relevant role for CaM at a later and arguably more critical cell cycle checkpoint in VSMC and are the first to directly demonstrate Ca 2ϩ sensitivity of its target. Indeed, it is interesting to note that although the studies of Kahl and Means and Taules and colleagues focused on the role of CaM in regulating the early-to-mid G 1 factors cyclin D/CDK4, we have examined the late G 1 -and S-phase factors cyclin E/CDK2. Collectively, the key emerging concept from these studies is that CaM mediates Ca 2ϩ sensitivities of both the early and late G 1 -to S-phase checkpoints through its interactions with cyclin D/CDK4/p21 cip1 and cyclin E/CDK2/p27 kip1 , respectively.
Although CaM-binding to cyclin E clearly increased the levels of Thr160-phosphorylated (ie, active) CDK2 in extracts from G 1 /S-synchronized VSMC ( Figure 4B ), we have yet to determine how precisely this occurs. Possible explanations include Ca 2ϩ /CaM-cyclin E-or Ca 2ϩ /CaM-dependent augmentation of (1) another kinase involved in CDK2 activation (namely CDK-activating kinase [CAK] , reviewed by Morgan 39 ) or (2) the release and/or degradation of the CDK2 inhibitor p27 kip1 from the otherwise mute cyclin E/CDK2/ p27 kip1 complex. As preliminary data from our laboratory indicate that the binding of CaM to cyclin E does not cause the release of p27 kip1 from cyclin E/CDK2 complex (data not shown), we suspect that the binding of CaM to cyclin E changes the conformation of the cyclin E/CDK2 complex, such that CDK2 can be more easily phosphorylated by CAK. Activation mechanisms of CaMBPs by CaM strongly support the concept that CaM activates its target proteins by altering their conformation. 40 Further studies will be required to define precisely the mechanisms underlying this observation and the potential involvement of CAK in the Ca 2ϩ /CaMcyclin E-dependent activation of CDK2. 
